Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors
StockNews.AI · 17 hours
AI Summary
Immunome announced the first patient has been dosed in the Phase 1 trial of IM-3050, a Lu-177 radioligand therapy targeting FAP in advanced solid tumors. The open-label, multicenter study will evaluate safety, dosimetry, PK, and preliminary anti-tumor activity, with dose escalation to identify a recommended expansion dose. This milestone provides a near-term clinical catalyst for IMNM as data emerge.
Sentiment Rationale
A Phase 1 dosing milestone for IM-3050 provides a visible near-term catalyst. Positive safety/dosimetry signals or early activity could lift IMNM shares; however, results are data-dependent and early-stage, constraining upside.
Trading Thesis
Bullish for IMNM in the next 12–18 months on early IM-3050 data.
Market-Moving
- First patient dosed in IM-3050 Phase 1 trial; near-term catalyst.
- FAP is expressed in about 75% of solid tumors; broad addressable opportunity.
- Lu-177 radioligand approach may offer novel therapy if safety and signals are favorable.
Key Facts
- IM-3050 is a FAP-targeted Lu-177 radioligand therapy.
- First patient dosed in IM-3050 Phase 1 open-label trial.
- FAP expressed in ~75% of solid tumors suggests broad potential.
- Phase 1 aims to assess safety, dosimetry, PK, and preliminary activity.
Companies Mentioned
- Immunome, Inc. (IMNM): Announced first patient dosed in IM-3050 Phase 1; potential near-term catalyst for stock.
Industry News
Category: Industry News. This fits as a clinical milestone update from a biotech, signaling potential near-term catalysts and validating the company's FAP-targeted strategy within Immunome's broader oncology portfolio.